All News

Found 65,032 articles

• Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

  4/16/2024

  Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.

• RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

  4/16/2024

  RenovoRx, Inc today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.

• Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

  4/16/2024

  Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

• VBI Vaccines Reports Full Year 2023 Financial Results

  4/16/2024

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

• Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

  4/16/2024

  Provectus Biopharmaceuticals, Inc. today announced additions to its executive leadership team, reflecting Provectus's dedication to enhancing shareholder value.

• Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

  4/16/2024

  Evergreen Theragnostics, Inc. today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.

• Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

  4/16/2024

  Johnson & Johnson announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases.

• GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

  4/16/2024

  GRI Bio, Inc. announced that the Korean Intellectual Property Office has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions.".

• Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

  4/16/2024

  Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved SELARSDI injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.

• Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring

  4/16/2024

  Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space.

• Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

  4/16/2024

  Nascent Biotech, Inc. announces that it is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

• St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

  4/16/2024

  Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

• IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

  4/16/2024

  Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).

• AlayaCare to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

  4/16/2024

  AlayaCare, a leading home-based care technology platform, will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

• Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

  4/16/2024

  Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.

• BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

  4/16/2024

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer.

• 

  Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech

  4/15/2024

  While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.

• GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

  4/15/2024

  GENFIT announced that it published in the April 15, 2024 French legal announcements bulletin n°46 its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

• Redemption Date Announced for Warrants - April 15, 2024

  4/15/2024

  Cassava Sciences, Inc. announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024.

• Acorda Therapeutics Announces Delisting from Nasdaq - April 15, 2024

  4/15/2024

  Acorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market.